MedTrace Logo

Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19

NCT05656443 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1246

Last updated 2023-10-12

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.

Conditions

Interventions

DRUG

GST-HG171/Ritonavir

dose of 150 mg GST-HG171 with 100 mg ritonavir

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Fujian Akeylink Biotechnology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-19
Primary Completion
2023-05-31
Completion
2023-07-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05656443 on ClinicalTrials.gov